Los Angeles Business Journal

Arrowhead Falls as Trials Halted

Thursday, December 1, 2016

Arrowhead Pharmaceuticals Inc. is firing 30 percent of its staff, halting all human trials, and going back to the lab after a seeing troubling safety concerns in a technology to cure liver disease, Bloomberg reports. Shares plunged 66 percent on Wednesday, and the once billion-dollar company’s market cap is now down to about $100 million.